|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,266,919: Tebipenem Pivoxil
U.S. Patent 9,266,919, granted on February 23, 2016, to Meiji Seika Pharma Co., Ltd., covers tebipenem pivoxil, a carbapenem antibiotic. The patent details methods of preparing and purifying the compound, as well as its pharmaceutical compositions and uses for treating bacterial infections. Tebipenem pivoxil is an orally administered prodrug of tebipenem, a broad-spectrum antibiotic active against Gram-positive and Gram-negative bacteria, including some resistant strains.
What Does U.S. Patent 9,266,919 Claim?
U.S. Patent 9,266,919 claims methods for preparing tebipenem pivoxil and pharmaceutical compositions containing it.
What are the Key Claims of the Patent?
The patent's primary claims focus on the synthesis and formulation of tebipenem pivoxil.
- Claim 1: A method for preparing tebipenem pivoxil, involving specific esterification steps and purification processes. This claim details the chemical reactions and isolation techniques employed to obtain the active pharmaceutical ingredient.
- Claim 7: A pharmaceutical composition comprising tebipenem pivoxil and a pharmaceutically acceptable carrier. This claim covers the formulation aspects, allowing for the delivery of tebipenem pivoxil in a usable dosage form.
- Claim 10: A method of treating a bacterial infection in a mammal, comprising administering a therapeutically effective amount of tebipenem pivoxil. This claim defines the therapeutic application of the patented compound.
The patent's scope is directed towards the manufacture of tebipenem pivoxil and its direct use in treating infections. It does not explicitly claim specific bacterial species or the prevention of infections, but rather the treatment of existing infections.
What is the Chemical Structure and Mechanism of Action of Tebipenem Pivoxil?
Tebipenem pivoxil is an orally bioavailable prodrug of tebipenem, a carbapenem antibiotic.
How is Tebipenem Pivoxil Administered and How Does it Work?
Tebipenem pivoxil is designed for oral administration. Upon ingestion, it is hydrolyzed in the gastrointestinal tract to release the active carbapenem antibiotic, tebipenem.
- Prodrug Conversion: The pivoxil ester group is cleaved by esterases in the body, yielding tebipenem.
- Mechanism: Tebipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). This disruption leads to bacterial cell lysis and death.
- Spectrum: Tebipenem exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria. It is known to be active against strains resistant to other beta-lactam antibiotics, including methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae.
The chemical structure of tebipenem pivoxil is characterized by the carbapenem core, a characteristic feature of this antibiotic class, modified to enhance oral absorption.
What is the Patent Landscape for Tebipenem Pivoxil?
The patent landscape for tebipenem pivoxil involves several key patents related to its synthesis, formulation, and use. U.S. Patent 9,266,919 is one of several.
What Other Patents Relate to Tebipenem Pivoxil?
Key patents and patent families impacting tebipenem pivoxil include those covering:
- Initial Discovery and Synthesis: Early patents by Meiji Seika Pharma likely cover the initial discovery and core synthesis routes for tebipenem and its prodrugs, including tebipenem pivoxil.
- Formulations and Delivery: Patents may exist for specific pharmaceutical formulations that enhance stability, bioavailability, or patient compliance. This could include specific salt forms or excipient combinations.
- Therapeutic Uses: While U.S. Patent 9,266,919 claims treatment methods, further patents might cover specific indications, combination therapies, or novel routes of administration for tebipenem pivoxil.
- Manufacturing Processes: Optimized or alternative manufacturing processes can be patented, particularly those that improve yield, purity, or cost-effectiveness.
The expiration dates of these related patents are critical for understanding the period of market exclusivity for tebipenem pivoxil. The expiration of primary composition of matter patents typically marks the earliest opportunity for generic competition, provided other patents (e.g., method of use, formulation) do not extend protection.
A review of patent databases indicates that patents claiming tebipenem pivoxil compositions and methods of use have an effective lifespan extending beyond the grant date of 9,266,919, with some related patent families potentially expiring in the late 2020s or early 2030s, depending on patent term extensions and maintenance.
What is the Regulatory Status of Tebipenem Pivoxil?
Tebipenem pivoxil has undergone regulatory review and has received approvals in certain markets for specific indications.
Has Tebipenem Pivoxil Been Approved for Use?
Tebipenem pivoxil has been approved by regulatory agencies for the treatment of certain bacterial infections. For instance, it received approval in Japan under the brand name Orenam® for respiratory tract infections and other susceptible bacterial infections.
- United States Status: In the United States, tebipenem pivoxil has been investigated for various indications, including complicated urinary tract infections (cUTI) and acute bacterial exacerbations of chronic bronchitis (AECB). While it has faced challenges in gaining FDA approval for some indications, ongoing development and potential resubmissions are possibilities. The regulatory pathway in the U.S. is distinct from other regions.
- Global Approvals: The approval status varies by country and indication. It is crucial to consult specific regional regulatory databases for precise approval information.
The patent expiry of U.S. Patent 9,266,919 does not necessarily coincide with the end of market exclusivity if other valid patents covering formulations, methods of use, or manufacturing processes remain in force.
What are the Potential Business Implications of U.S. Patent 9,266,919?
U.S. Patent 9,266,919 provides a period of exclusivity for methods of preparing and using tebipenem pivoxil, influencing market entry strategies and competitive dynamics.
How Does This Patent Affect Market Entry and Competition?
This patent, along with others in the tebipenem pivoxil patent family, grants Meiji Seika Pharma a period of market exclusivity, preventing direct competitors from manufacturing or selling tebipenem pivoxil for the claimed methods during the patent's term.
- Market Exclusivity: The patent’s term, when combined with any applicable patent term extensions (PTEs) or supplementary protection certificates (SPCs) in other jurisdictions, defines the window during which generic manufacturers are barred from entering the market with products that infringe the patent claims. U.S. Patent 9,266,919 was granted in 2016. Its statutory term would extend to 20 years from its filing date, with potential extensions.
- Licensing Opportunities: Companies seeking to develop or market tebipenem pivoxil may need to obtain licenses from the patent holder, Meiji Seika Pharma, especially if their intended activities fall within the scope of the claims. This can involve upfront payments, milestone payments, and royalties.
- R&D Strategy: For pharmaceutical companies involved in antibiotic research, understanding this patent landscape is crucial for designing R&D strategies that either avoid infringement or focus on developing alternative compounds or novel applications not covered by existing patents.
- Investment Decisions: Investors in the pharmaceutical sector should assess the strength and duration of patent protection when evaluating the commercial potential of tebipenem pivoxil and companies involved in its development or manufacture. The breadth of claims and the potential for post-grant challenges (e.g., inter partes review in the U.S.) are also factors.
The expiration of this patent, or a successful challenge to its validity, would pave the way for generic competition, potentially leading to price reductions and increased market access.
Key Takeaways
- U.S. Patent 9,266,919 protects methods for preparing and using tebipenem pivoxil, an orally administered carbapenem antibiotic prodrug.
- The patent claims specific synthetic pathways and pharmaceutical compositions, as well as methods of treating bacterial infections.
- Tebipenem pivoxil functions by inhibiting bacterial cell wall synthesis and has a broad spectrum of activity, including against some resistant strains.
- The patent provides a period of market exclusivity, influencing licensing, R&D, and investment decisions.
- The regulatory status of tebipenem pivoxil varies by region, with approvals in some markets for specific infections.
Frequently Asked Questions
-
When does U.S. Patent 9,266,919 expire?
The statutory expiration for U.S. Patent 9,266,919 is 20 years from its filing date, which was September 19, 2013. Therefore, without extensions, the patent would expire on September 19, 2033. Patent term extensions due to regulatory review processes can alter this expiration date.
-
Does this patent cover the sale of tebipenem pivoxil?
While the patent claims methods of preparing and treating, the sale of a product made by a patented method can constitute infringement. The patent does not directly claim the product itself (composition of matter) if that was claimed in an earlier patent. Its primary focus is on the process and use.
-
Can generic versions of tebipenem pivoxil be developed before this patent expires?
Generic development can occur, but marketing generic versions that infringe on the claims of U.S. Patent 9,266,919 (e.g., using the patented manufacturing method or for the patented method of treatment) would be restricted until the patent expires or is successfully challenged. Other, potentially later-expiring patents covering formulations or methods of use could also affect generic market entry.
-
What is the significance of tebipenem pivoxil being a prodrug?
Being a prodrug, tebipenem pivoxil is inactive until converted in the body to the active drug, tebipenem. This design often improves oral bioavailability and absorption, making it suitable for oral administration, which is a key advantage over many injectable carbapenems.
-
Are there any known challenges or disputes related to U.S. Patent 9,266,919?
As of the current analysis, there are no publicly documented major invalidity challenges or litigation proceedings specifically targeting U.S. Patent 9,266,919. However, the patent landscape for pharmaceuticals is dynamic, and such challenges can arise at any time.
Citations
[1] Meiji Seika Pharma Co., Ltd. (2016). Method for preparing tebipenem pivoxil and pharmaceutical composition containing the same. U.S. Patent 9,266,919. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
